Vivos Therapeutics, Inc. (VVOS)

Vivos Therapeutics Analyst Ratings

VVOS's stock price has decreased by -67.22% in the past year and price targets may not have had time to catch up.

• Total Analysts: 2
• Consensus Rating: Strong Buy
• Price Target: $6.25
• Upside: +434.83%

Ratings History

Filter results

Analyst	Firm	Rating	Rating	Action	Price Target	Upside	Date
Lucas Ward Ascendiant Capital	Ascendiant Capital	Strong Buy Maintains $6.5 → $5.5	Strong Buy	Maintains	$6.5 → $5.5	+370.65%	Dec 3, 2025
Yi Chen HC Wainwright & Co.	HC Wainwright & Co.	Strong Buy Initiates $7	Strong Buy	Initiates	$7	+499.01%	Nov 17, 2025
Lucas Ward Ascendiant Capital	Ascendiant Capital	Strong Buy Maintains $6.2 → $6.5	Strong Buy	Maintains	$6.2 → $6.5	+456.22%	Sep 9, 2025
Lucas Ward Ascendiant Capital	Ascendiant Capital	Strong Buy Maintains $6.6 → $6.2	Strong Buy	Maintains	$6.6 → $6.2	+430.55%	Apr 15, 2025
Lucas Ward Ascendiant Capital	Ascendiant Capital	Strong Buy Reiterates $6.6	Strong Buy	Reiterates	$6.6	+464.78%	Nov 20, 2024
Scott Henry Alliance Global Partners	Alliance Global Partners	Strong Buy Maintains $8.25 → $6	Strong Buy	Maintains	$8.25 → $6	+413.43%	Nov 19, 2024
Lucas Ward Ascendiant Capital	Ascendiant Capital	Strong Buy Maintains $6.4 → $6.6	Strong Buy	Maintains	$6.4 → $6.6	+464.78%	Aug 20, 2024
Edward Woo Ascendiant Capital	Ascendiant Capital	Strong Buy Initiates $63	Strong Buy	Initiates	$63	+5,248.28%	Jan 17, 2023
Scott Henry Roth Capital	Roth Capital	Strong Buy Maintains $275 → $250	Strong Buy	Maintains	$275 → $250	+21,293.12%	Aug 13, 2021
Scott Henry Roth Capital	Roth Capital	Strong Buy Maintains $300 → $275	Strong Buy	Maintains	$300 → $275	+23,432.43%	May 18, 2021
Alexander Nowak Craig-Hallum	Craig-Hallum	Strong Buy Initiates $300	Strong Buy	Initiates	$300	+25,571.74%	Jan 11, 2021
Scott Henry Roth Capital	Roth Capital	Strong Buy Initiates $300	Strong Buy	Initiates	$300	+25,571.74%	Jan 5, 2021